Project description
Innovative technology for brain drug delivery starting from paediatric brain tumours
Central nervous system (CNS) diseases affect millions of people worldwide. However, most of these conditions lack effective treatments because drug candidates do not cross the blood-brain barrier (BBB). As a result, these disorders lead to disability and mortality. Funded by the European Innovation Council, the Gate2Brain project introduces a technological platform capable of crossing the BBB and delivering therapeutic cargoes of different modalities to the CNS that are unable to reach the brain unaided. This platform relies on small peptide shuttles and proposes a new therapeutic approach, G2B-002, to combat untreatable paediatric brain tumours with intact BBB as a first indication that will benefit from the technology. The technology enables non-invasive and receptor-specific transport of drugs across the BBB, and could be expanded beyond paediatric tumours.
Objective
In 2019, 30 million people worldwide were diagnosed with some form of CNS disorder and most of them lack effective treatment. This is largely explained by the fact that most of developed therapeutic molecules do not contain the appropriate properties to cross the BBB. Consequently, CNS disorders are the first cause of disability, and the second of mortality worldwide. Gate2Brain is a technologic platform based on a set of small peptide-shuttles that have the capacity to cross the BBB and carry to the CNS therapeutic cargoes that cannot reach the brain unaided. G2B-002, our flagship product, is a new therapeutic approach to fight against untreatable pediatric brain tumors with intact BBB. G2B novel delivery technology provides a non-invasive, non-antigenic, stable, soluble, and receptor-specific way to transport drugs across the BBB to reach the CNS. Our technology has the potential to be applied in a wide number of therapeutic areas and in transport through various biological barriers.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
You need to log in or register to use this function
Keywords
- Immunotoxicity
- peptide synthesis
- drug-shuttles
- blood-brain barrier
- therapeutic molecules
- paediatric oncology
- peptide-shuttles
- Brain Drug Delivery Systems
- Drug delivery
- Central Nervous System
- Glioblastoma
- Drug development
- Pharmaceutical industry
- Brain delivery
- Solubility
- peptides
- peptide chemistry
- peptide drug conjugates
Programme(s)
- HORIZON.3.1 - The European Innovation Council (EIC) Main Programme
Funding Scheme
HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended FinanceCoordinator
08028 Barcelona
Spain
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.